The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Venxxiva ™ (tiopronin delayed-release tablet) has been made available for the treatment of cystinuria.

BOSTON, March 18, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by ...

ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA ® ...

Cystinuria is an inherited genetic condition that involves changes in the extent of reabsorption of cystine and other dibasic acids from the urine and into the bloodstream. As a result, affected ...

Cystinuria is a chronic condition that cannot be cured. However, certain management techniques can help to prevent the formation of stones in the kidneys and their resulting complications. Firstly, it ...

PARIS, January 29, 2025--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization ...

The US Food and Drug Administration (FDA) has approved an enteric-coated delayed-release formulation of tiopronin (Thiola EC, Retrophin) for treatment of cystinuria, a rare inherited disorder that ...

A rare condition in which stones made from an amino acid called cystine form in the kidney, ureter and bladder is known as cystinuria. This condition can be passed down through generations. A person ...

"Cystinuria Pipeline 2025"DelveInsight's,“Cystinuria - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cystinuria pipeline landscape. It ...

Cystinuria is an autosomal recessive disorder that is characterized by an impaired tubular transport of cystine and dibasic aminoacids, resulting in cystine urolithiasis. The transport of these amino ...

Hypotonia–cystinuria syndrome (HCS) is a recessive disorder caused by microdeletions of SLC3A1 and PREPL on chromosome 2p21. Patients present with generalized hypotonia at birth, failure to thrive, ...